Cassava Sciences (NASDAQ:SAVA - Free Report) had its target price boosted by HC Wainwright from $124.00 to $131.00 in a research report report published on Friday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.
Cassava Sciences Stock Up 7.2 %
Shares of NASDAQ:SAVA traded up $1.56 during trading on Friday, reaching $23.12. 773,533 shares of the company's stock traded hands, compared to its average volume of 794,397. Cassava Sciences has a fifty-two week low of $12.32 and a fifty-two week high of $32.10. The firm has a market cap of $1.11 billion, a PE ratio of -10.52 and a beta of -0.38. The company has a 50-day simple moving average of $21.33 and a 200-day simple moving average of $21.02.
Cassava Sciences (NASDAQ:SAVA - Get Free Report) last posted its earnings results on Wednesday, February 28th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.10). On average, equities research analysts forecast that Cassava Sciences will post -2.01 EPS for the current year.
Institutional Investors Weigh In On Cassava Sciences
Several institutional investors have recently bought and sold shares of SAVA. Jump Financial LLC acquired a new stake in Cassava Sciences in the 3rd quarter worth about $1,716,000. Cable Car Capital LLC purchased a new stake in shares of Cassava Sciences in the fourth quarter valued at approximately $1,204,000. Vanguard Group Inc. grew its position in shares of Cassava Sciences by 1.4% in the first quarter. Vanguard Group Inc. now owns 2,356,480 shares of the company's stock valued at $47,813,000 after purchasing an additional 31,854 shares in the last quarter. Clear Creek Financial Management LLC grew its position in shares of Cassava Sciences by 29.0% in the fourth quarter. Clear Creek Financial Management LLC now owns 134,605 shares of the company's stock valued at $3,030,000 after purchasing an additional 30,265 shares in the last quarter. Finally, Virtu Financial LLC grew its position in shares of Cassava Sciences by 120.3% in the fourth quarter. Virtu Financial LLC now owns 49,128 shares of the company's stock valued at $1,106,000 after purchasing an additional 26,824 shares in the last quarter. 38.05% of the stock is currently owned by institutional investors and hedge funds.
About Cassava Sciences
(
Get Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Featured Stories
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
